ECOR
electroCore, Inc.4.7900
+0.0200+0.42%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Key Stats
Market Cap
38.30MP/E (TTM)
-Basic EPS (TTM)
-1.71Dividend Yield
0%Recent Filings
10-K
8-K
8-K
Record 26% revenue growth
electroCore issued preliminary unaudited 2025 results on January 20, 2026, projecting record revenue of ~$31.8–$32.0 million, up 26% from 2024's $25.2 million, with Q4 at ~$9.0–$9.2 million, up 30%. Total cash stood at $11.6 million, down from $13.2 million in Q3. Figures are preliminary. Changes could be material.
10-Q
Q3 FY2025 results
electroCore posted Q3 net sales of $8.7M, up 33% y/y from $6.6M, with gross margin edging to 86% from 84% on stronger prescription device and wellness product demand—VA sales hit 69.9%. Operating loss widened slightly to $2.9M from $2.7M as SG&A climbed 27% y/y on sales investments, while net loss reached $3.4M versus $2.5M, the gap reflecting $0.4M acquisition costs and Avenue debt interest. Cash plus marketable securities stood at $13.2M after $7.5M Tranche 1 draw (due 2029 at 12.5%, $6.5M net); operating cash burn was $6.6M YTD. Closed NURO acquisition May 2025 with CVR payouts tied to Quell sales. Patent fight with Pulsetto drags on.
8-K
Q3 sales up 33%
electroCore posted Q3 net sales of $8.7 million, up 33% from $6.6 million last year, fueled by prescription devices and record $1.7 million Truvaga sales. Gross margin hit 86%. Revenue soared. Cash stands at $13.2 million; FY2025 guidance raised to $31.5-$32.5 million, targeting positive adjusted EBITDA in H2 2026.
BWAY
Brainsway Ltd.
16.87-0.47
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.60+0.00
ELMD
Electromed, Inc.
29.88+0.28
EMED
Electromedical Technologies, In
0.00+0.00
EW
Edwards Lifesciences Corporatio
85.32+1.94
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
NXL
Nexalin Technology, Inc.
0.81-0.01
STME
Stimcell Energetics, Inc.
0.37-0.04
VYCO
Vycor Medical, Inc.
0.16+0.00